Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naloxone does not affect cigarette smoking.

R Nemeth-Coslett, R R Griffiths

    Psychopharmacology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Naloxone, an opioid antagonist, did not alter cigarette smoking behaviors in a study of healthy volunteers. These findings do not support the theory that endogenous opioids are responsible for smoking reinforcement.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.

    Neuropharmacology·2022
    Same author

    Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

    Psychopharmacology·2006
    Same author

    An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.

    Behavioural pharmacology·2005
    Same author

    Physical dependence in baboons chronically treated with low and high doses of diazepam.

    Behavioural pharmacology·2003
    Same author

    Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166).

    Behavioural pharmacology·2003
    Same author

    Alcohol and triazolam: differential effects on memory, psychomotor performance and subjective ratings of effects.

    Behavioural pharmacology·2002
    Same journal

    Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

    Psychopharmacology·2026
    Same journal

    Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

    Psychopharmacology·2026
    Same journal

    Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

    Psychopharmacology·2026
    Same journal

    Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

    Psychopharmacology·2026
    Same journal

    Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

    Psychopharmacology·2026
    Same journal

    OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study.

    Psychopharmacology·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Addiction Research

    Background:

    • The reinforcing effects of cigarette smoking are hypothesized to be mediated by endogenous opioids.
    • Understanding the neurobiological underpinnings of nicotine addiction is crucial for developing effective cessation strategies.

    Purpose of the Study:

    • To investigate the role of endogenous opioids in mediating the reinforcing properties of cigarette smoking.
    • To examine the effects of naloxone, an opioid antagonist, on various measures of smoking behavior.

    Main Methods:

    • Seven healthy volunteers participated in a double-blind, placebo-controlled study.
    • Subjects received intramuscular injections of varying doses of naloxone hydrochloride or placebo.
    • Smoking behavior was assessed during a 2-hour ad libitum smoking session in a naturalistic laboratory setting.

    Related Experiment Videos

    Main Results:

    • Naloxone administration did not significantly affect the number of cigarettes smoked, the number of puffs taken, or expired air carbon monoxide levels.
    • A dose-related increase in self-reported yawning, stretching, and relaxation was observed with naloxone treatment.
    • No significant impact of naloxone on core smoking measures was detected.

    Conclusions:

    • The results do not provide evidence supporting the endogenous opioid theory of smoking reinforcement.
    • Opioid antagonists like naloxone do not appear to modulate the primary reinforcing effects of cigarette smoking.
    • Further research may be needed to elucidate the complex neurochemical pathways involved in nicotine addiction.